Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Identifying targeted therapy combination for refractory colorectal cancer using micro-organospheres.
Authors
Shengli Ding
Xilis, Inc., Durham, NC;
Shengli Ding , Preeti Kanikarla Marie , Ray Zhang , Nicholas Baro , Daniel W Brown , Alan Bohn , Kelly Pittman , Marcin Paduch , Shiaowen David Hsu , Scott Kopetz , Xiling Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Diagnostics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 27)
DOI
10.1200/JCO.2023.41.4_suppl.27
Abstract #
27
Poster Bd #
B2
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.
First Author: Saikat Chowdhury
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results.
First Author: Anwaar Saeed